Bluejay Diagnostics (BJDX) Liabilities and Shareholders Equity (2020 - 2026)

Bluejay Diagnostics has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $5.6 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 6.07% year-over-year to $5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.0 million (down 22.91% YoY) and the FY2025 annual result came in at $7.1 million, up 6.94% from the prior year.
• Liabilities and Shareholders Equity fell to $5.6 million in Q1 2026 per BJDX's latest filing, from $7.1 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $20.1 million in Q1 2022 and troughed at $4.9 million in Q4 2023.
• A 5-year average of $9.4 million and a median of $8.2 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity jumped 333.54% in 2022, then slumped 63.99% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $13.5 million in 2022, then plunged by 63.99% to $4.9 million in 2023, then jumped by 36.74% to $6.7 million in 2024, then rose by 6.94% to $7.1 million in 2025, then declined by 21.36% to $5.6 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $5.6 million, $7.1 million, and $4.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.